Medical Tech Power Stock Simplifies Surgery, Leads Industry

Noninvasive medical tech demand is on the rise. This Power Stock tops the market. [Turn Your Images On] --------------------------------------------------------------- In a recent Money & Markets team meeting, Adam shared an article from Tom McClellan, who stated the bear market wouldn’t bottom out until 2024. It got the whole office talking … some said we’ve already hit it, while others said we haven’t seen it yet. So next week, Adam, Charles and I will share the indicators we’re using to track the bear market and see what they say about the expected bottom. And we want to get you in on the action with one simple question: What’s the exact day you expect the bear market to bottom out? The person who calls it the closest will get a $500 gift card. [Click here](mailto:feedback@moneyandmarkets.com?subject=Bear%20Market%20Prediction) to email your prediction to [Feedback@MoneyandMarkets.com](mailto:Feedback@MoneyandMarkets.com?subject=Bear%20Market%20Prediction). — Matt. --------------------------------------------------------------- Stock Power Ratings [Medical Tech Power Stock Simplifies Surgery, Leads Industry]( [Turn Your Images On] [Matt Clark, Research Analyst]( A bit ago, my friend Jeff was in tremendous pain. His physician informed him he had excess tissue enlarging his prostate gland. Instead of the usual painful surgery followed by a long recovery, a surgeon performed an ablation. It was a minimally invasive procedure that used low-energy radio frequencies to remove the excess tissue. While Jeff feels 100% better, his story put me on track for the stock I’ll share today. Using Chief Investment Strategist Adam O’Dell’s proprietary six-factor Stock Power Ratings system, I found a “Strong Bullish” company that manufactures minimally invasive medical devices: - Its recent quarterly revenue was 36.7% higher than a year ago. - The stock jumped 32% since the middle of July. - It’s 9% off its 52-week high. And this medical technology stock will continue its strong performance in 2022 and beyond. [Here’s why.](       --------------------------------------------------------------- FROM OUR PARTNERS [Forget Electric Vehicles — Follow the Money]( Over $100 billion has been invested into this “future tech.” Companies such as Toyota, Honda, Ford, even Apple and Amazon have all invested big. What are these auto and tech companies up to? [It’s this:]( a tech that could trigger a $7 trillion market by 2050. It’s set to grow 63,000% ... this decade alone. [Watch this video presentation for details.]( --------------------------------------------------------------- Advanced Medical Technology Leads Industry Medical technology has advanced leaps and bounds from where it was a decade ago. Virtual reality, artificial intelligence, genomics (aka DNA science) and other advancements are still in their infancy. This industry is only going to grow from here: [Turn Your Images On] [(Click here to view larger image.)]( The chart above shows the revenue generated from medical technology worldwide. In 2014, the industry recorded $379.7 billion in revenue. Medical data firm Evaluate expects that to grow more than 56% by 2024. Bottom line: Continued advancements in medical technology will push the industry to new records in the coming years. High Growth + Strong Momentum: EDAP TMS S.A. Surgeons are always looking for ways to simplify procedures. They want to do them with as few incisions as possible. EDAP TMS S.A. (Nasdaq: EDAP) is a French company that has developed these techniques since 1979. It’s focused on developing devices for urological disorders (like kidney stone removal and prostate problems). These devices ensure the most relief with the least amount of invasive surgery. [Turn Your Images On] [(Click here to view larger image.)]( In 2020, EDAP’s total annual revenue was $40.9 million. The company expects to gain 82.4% more in revenue by 2024. Let’s look at how this medical technology stock has performed. [Turn Your Images On] [(Click here to view larger image.)]( Since the middle of July 2022, EDAP stock has jumped 32%. EDAP continues to outperform its other medical device industry peers — which are down over 12 months. EDAP shows the “maximum momentum” we love to see in stocks. --------------------------------------------------------------- [5 Inflation-Busting Stocks]( Consumer goods prices are soaring … and you’re paying the price. But you can fight back with a class of stocks that beats back inflation, stagflation and … yes, even recessions … by giving investors exactly what they need: recurring income. I’ve uncovered five of the very best inflation-busting stocks … including a stock with a massive 14% yield that’s so consistent with its payouts, I call it my “sure thing.” [Click here now for all the details.]( --------------------------------------------------------------- EDAP TMS’ Stock Power Ratings Using Adam’s six-factor Stock Power Ratings system, EDAP TMS S.A. stock scores a 90 overall. That means we’re “Strong Bullish” on the stock and expect it to beat the broader market by at least three times over the next 12 months. [Turn Your Images On]( EDAP’s Stock Power Ratings in October 2022. EDAP rates in the green on five of our six factors: - Size — With a market cap of $276.1 million, EDAP is the perfect size to produce even stronger gains. It scores a 99 on size. - Growth — EDAP scores a 91 on growth, with a one-year earnings-per-share growth rate of 138.3% and a 20.7% growth in sales from its last quarter. - Momentum — EDAP stock is up 32% since the middle of July and has weathered the recent stock market sell-off better than most. It scores an 87 on momentum. - Quality — Returns on assets, equity and investment are all negative in the overall medical device industry. But EDAP boasts positive gains on all three metrics. It scores a 68 on quality. - Volatility — EDAP’s recent climb has met little resistance. It scores a 66 on volatility. EDAP’s nice run higher since July shows the “maximum momentum” we love to see in stocks. But that has pushed its value rating down a bit to 11. Bottom line: Every day, there are new advances in medical technology. And the demand for more new technology will grow as we continue to find new and innovative ways to treat ailments. This is why EDAP is a must-have for your portfolio. While EDAP innovates on the medical device side, Adam O’Dell, our chief investment strategist, is focused on the genomics mega trend. And you can learn about his No. 1 stock to invest in this mega trend by [watching his “Imperium” presentation.]( [Click here to do so now]( and find out why Adam’s highest convictions within medical innovation lie in genomics. Safe trading, [Matt Clark signature] Matt Clark, CMSA® Research Analyst, Money & Markets Suggested Stories: [Bear Market Playbook: One Value Stock to Buy — and One to Avoid]( [Look Beyond Texas: High-Growth Energy Co. in No. 2 Oil State]( --------------------------------------------------------------- [Turn Your Images On] 1957: The Soviet Union launched Sputnik 1 into space to become the first artificial satellite to orbit the Earth. It inaugurated the Space Age but heightened tensions of the Cold War between the USSR and the U.S. Privacy Policy The Money & Markets, P.O. Box 8378, Delray Beach, FL 33482. To ensure that you receive future issues of Money & Markets, please add info@mb.moneyandmarkets.com to your address book or [whitelist]( within your spam settings. For customer service questions or issues, please contact us for assistance. The mailbox associated with this email address is not monitored, so please do not reply. Your feedback is very important to us so if you would like to contact us with a question or comment, please click here: [( Legal Notice: This work is based on what we've learned as financial journalists. It may contain errors and you should not base investment decisions solely on what you read here. It's your money and your responsibility. Nothing herein should be considered personalized investment advice. Although our employees may answer general customer service questions, they are not licensed to address your particular investment situation. Our track record is based on hypothetical results and may not reflect the same results as actual trades. Likewise, past performance is no guarantee of future returns. Certain investments carry large potential rewards but also large potential risk. Don't trade in these markets with money you can't afford to lose. Money & Markets permits editors of a publication to recommend a security to subscribers that they own themselves. However, in no circumstance may an editor sell a security before our subscribers have a fair opportunity to exit. Any exit after a buy recommendation is made and prior to issuing a sell notification is forbidden. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. (c) 2022 Money & Markets, LLC. All Rights Reserved. Protected by copyright laws of the United States and treaties. This Newsletter may only be used pursuant to the subscription agreement. Any reproduction, copying, or redistribution, (electronic or otherwise) in whole or in part, is strictly prohibited without the express written permission of Money & Markets. P.O. Box 8378, Delray Beach, FL 33482. (TEL: 800-684-8471) Remove your email from this list: [Click here to Unsubscribe](